A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2013

At a glance

  • Drugs Beclometasone (Primary)
  • Indications Seasonal allergic rhinitis; Tree pollen hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Sep 2012 Results published in Allergy and Asthma Proceedings.
    • 22 May 2012 Actual patient number changd from 484 to 340 as reported by ClinicalTrials.gov.
    • 16 Nov 2010 Results presented at the ACAAI-2010, according to a Teva media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top